Jump to main content
Jump to site search

All chapters
Previous chapter Next chapter

CHAPTER 6

Drugs that Target the Glutamate Synapse: Implications for the Glutamate Hypothesis of Schizophrenia

This chapter describes a brief history and the recent evolution of the glutamate hypothesis of schizophrenia: from its divergence with the dopamine hypothesis to its implication in the widespread cortical and subcortical dysfunction found in schizophrenia. It also describes some of the working hypotheses about the integration of glutamate, along with other neurotransmitter systems, in the more generalized etiology of the disease, ultimately better clarifying the pathophysiology and conceivable therapeutic pharmacology of schizophrenia. Pertinent animal models of the disease state are highlighted to showcase some of the tools used in the development and verification of new pharmacological treatments that target the glutamate synapse, either through a direct or indirect improvement of glutamatergic signalling. The chapter concludes with a discussion of new potential therapeutic targets and strategies to improve neuronal function at the glutamate synapse.

Publication details


Print publication date
13 May 2015
Copyright year
2015
Print ISBN
978-1-78262-026-6
PDF eISBN
978-1-78262-249-9
ePub eISBN
978-1-78262-504-9
From the book series:
Drug Discovery